Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Effects of Diabetes and Hyperlipidemia in Physiological Conditions - A Review

Abstract

Background

Diabetes mellitus (DM) is an autoimmune manifestation defined by persistent hyperglycemia and alterations in protein, fatty substances, and carbohydrate metabolism as an effect of problems with the secretion of insulin action or both. Manifestations include thirst, blurred eyesight, weight loss, and ketoacidosis, which can majorly lead to coma. There are different types of diabetes according to class or by cellular level. They are interrelated with hyperlipidemia as they are involved in the metabolism and regulation of physiological factors. Most parameters are seen at cellular or humoral levels, yet the underlying concern remains the same.

Objective

To create a systematic correlation between the disease and locate the exact mechanism and receptors responsible for it. So, this article covers a proper way to resolve the conditions and their manifestation through literacy and diagrammatic.

Conclusion

Hence, this will be an insight for many scholars to understand the exact mechanism involved in the process.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998289406240214093815
2024-09-03
2024-10-12

  • From This Site

    /content/journals/cdr/10.2174/0115733998289406240214093815
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WHO Study group diabetes mellitus, Technical report series. World Health Organ. Tech. Rep. Ser. 1985 727 1 113
    [Google Scholar]
  2. Singh N. Kesherwani R. Tiwari A.K. Patel D.K. A review on diabetes mellitus. J. Pharm. Innov. 2016 5 7 36 40 27717130
    [Google Scholar]
  3. Kumar C.R. Basic Pathology, Prism PVT. 5th ed Limited Bangalore 1992 569 587
    [Google Scholar]
  4. Ross and Wilson Anatomy and pathophysiology in health and illness. 11th ed Churchill Livingstone Elsevier 2010 227 229
    [Google Scholar]
  5. Global burden of disease collaborative network.. 2020. Available from: https://vizhub.healthdata.org/gbd-results/
  6. Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997 20 7 1183 1197 10.2337/diacare.20.7.1183 9203460
    [Google Scholar]
  7. American Diabetes Association Diagnosis and classification of diabetes mellitus. 2014
    [Google Scholar]
  8. Tobias D.K. Hu F.B. Chavarro J. Rosner B. Mozaffarian D. Zhang C. Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus. Arch. Intern. Med. 2012 172 20 1566 1572 10.1001/archinternmed.2012.3747 22987062
    [Google Scholar]
  9. Kim C. Newton K.M. Knopp R.H. Gestational diabetes and the incidence of type 2 diabetes: A systematic review. Diabetes Care 2002 25 10 1862 1868
    [Google Scholar]
  10. American diabetes association. Standards of medical care in diabetes--2014. Diabetes Care 2014 37 S14 S80 10.2337/dc14‑S014 24357209
    [Google Scholar]
  11. Landon M.B. Spong C.Y. Thom E. A multicenter, randomized trial of treatment for mild gestational diabetes. N. Engl. J. Med. 2009 361 14 1339 1348 10.1056/NEJMoa0902430 19797280
    [Google Scholar]
  12. Crowther C.A. Hiller J.E. Moss J.R. McPhee A.J. Jeffries W.S. Robinson J.S. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N. Engl. J. Med. 2005 352 24 2477 2486 10.1056/NEJMoa042973 15951574
    [Google Scholar]
  13. Vandorsten J.P. Dodson W.C. Espeland M.A. NIH consensus development conference: Diagnosing gestational diabetes mellitus. NIH Consens. State Sci. Statements 2013 29 1 1 31 23748438
    [Google Scholar]
  14. Kahn C.R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994 43 8 1066 1085 10.2337/diab.43.8.1066 8039601
    [Google Scholar]
  15. Horvath K Koch K Jeitler K Effects of treatment in women with gestational diabetes mellitus: Systematic review and metaanalysis. BMJ 2010 340 apr01 1 c1395 10.1136/bmj.c1395 20360215
    [Google Scholar]
  16. Weyer C. Bogardus C. Mott D.M. Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 1999 104 6 787 794 10.1172/JCI7231 10491414
    [Google Scholar]
  17. Surampudi P.N. John-Kalarickal J. Fonseca V.A. Emerging concepts in the pathophysiology of type 2 diabetes mellitus. Mt. Sinai J. Med. 2009 76 3 216 226 10.1002/msj.20113 19421965
    [Google Scholar]
  18. Olokoba A.B. Obateru O.A. Olokoba L.B. Type 2 diabetes mellitus: A review of current trends. Oman Med. J. 2012 27 4 269 273 10.5001/omj.2012.68 23071876
    [Google Scholar]
  19. Zimmet P. Alberti K.G.M.M. Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001 414 6865 782 787 10.1038/414782a 11742409
    [Google Scholar]
  20. Wild S. Roglic G. Green A. Sicree R. King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 5 1047 1053 10.2337/diacare.27.5.1047 15111519
    [Google Scholar]
  21. Deshmukh C.D. Diabetes mellitus: A review. IJPAB 2015 3 3 224 230
    [Google Scholar]
  22. Bergman R.N. Steil G.M. Bradley D.C. Watanabe R.M. Modeling of insulin action in vivo. Annu. Rev. Physiol. 1992 54 1 861 883 10.1146/annurev.ph.54.030192.004241 1562195
    [Google Scholar]
  23. Robertson R.P. Antagonist: Diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis. J. Lab. Clin. Med. 1995 125 5 560 564 7738421
    [Google Scholar]
  24. Rang H.P. Dale M.M. Pharmacology, sixth edition, churchill livingstone. The Endocrine Pancreas and Control of Blood Glucose. Churchill Livingstone 2008 397 409
    [Google Scholar]
  25. Sims-Robinson C. Kim B. Rosko A. Feldman E.L. How does diabetes accelerate Alzheimer disease pathology? Nat. Rev. Neurol. 2010 6 10 551 559 10.1038/nrneurol.2010.130 20842183
    [Google Scholar]
  26. Verma S Gupta M Popli H Aggarwal G Diabetes mellitus treatment using herbal drugs. 2018
    [Google Scholar]
  27. Tabatabaeimalazy O. Targeting metabolic disorders by natural products. J. Diabetes Metab. Disord. 2015 ••• 14 57
    [Google Scholar]
  28. Abutaleb M.H. Diabetes Mellitus: An overview. Pharm. Pharmacol. Int. J. 2016 4 5 406 411 10.15406/ppij.2016.04.00087
    [Google Scholar]
  29. Joshi S.K. Shrestha S. Diabetes mellitus: A review of its associations with different environmental factors. Kathmandu Univ. Med. J. 2010 8 29 109 115 21209519
    [Google Scholar]
  30. Mohan V. Pradeepa R. Epidemiology of diabetes in different regions of India. Indian J. Ophthalmol. 2009 69 11 2932 2938
    [Google Scholar]
  31. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012 35 Suppl. 1 S64 S71 22187472
    [Google Scholar]
  32. American diabetes association. Standards of medical care in diabetes--2008. Diabetes Care 2008 31 S12 S54 10.2337/dc08‑S012 18165335
    [Google Scholar]
  33. Schlichtmann J. Graber M.A. Hematologic, electrolyte, and metabolic disorders. The Family Practice Handbook. 3rd ed Graber M.A. Toth P.P. Herting R.L. St. Louis, Missouri Mosby-Year Book Inc. 1997 192 251
    [Google Scholar]
  34. Wing R.R. Koeske R. Epstein L.H. Nowalk M.P. Gooding W. Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch. Intern. Med. 1987 147 10 1749 1753 10.1001/archinte.1987.00370100063012 3310940
    [Google Scholar]
  35. Kartono A. Irawati F.D. Setiawan A.A. Syafutra H. Sumaryada T. The effects of physical exercise on the insulin-dependent diabetes mellitus subjects using the modified minimal model. Int. J. Pharm. Pharm. Sci. 2017 9 2 179 10.22159/ijpps.2017v9i2.15621
    [Google Scholar]
  36. American diabetes association. Clinical practice recommendations 1995. Position statement: Diabetes mellitus and exercise. Diabetes Care 1995 18 28 10.2337/diacare.18.1.S28
    [Google Scholar]
  37. Thangasami S.R. Chandani A.L. Thangasami S. Emphasis of yoga in the management of diabetes. J. Diabetes Metab. 2015 6 10 2 10.4172/2155‑6156.1000613
    [Google Scholar]
  38. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 1999 131 4 281 303 10.7326/0003‑4819‑131‑4‑199908170‑00008 10454950
    [Google Scholar]
  39. Nissen S.E. Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007 356 24 2457 2471 10.1056/NEJMoa072761 17517853
    [Google Scholar]
  40. Cryer P.E. Davis S.N. Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003 26 6 1902 1912 10.2337/diacare.26.6.1902 12766131
    [Google Scholar]
  41. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int. J. Obes. 2002 26 S3 S18 S24 10.1038/sj.ijo.0802173 12174319
    [Google Scholar]
  42. Ho P.M. Rumsfeld J.S. Masoudi F.A. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch. Intern. Med. 2006 166 17 1836 1841 10.1001/archinte.166.17.1836 17000939
    [Google Scholar]
  43. Svensson M. Eriksson J.W. Dahlquist G. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: A population-based study in northern Sweden. Diabetes Care 2004 27 4 955 962
    [Google Scholar]
  44. Rathod S. Akshay J. Rode A. Shravan S. A review on diabetics. Int. Multidiscip. Res. J. 2023 5 3 1 13 10.2337/diacare.27.4.955 15047655
    [Google Scholar]
  45. Mumthaj P. Natarajan P. Janani A.M. A global review article on hyperlipidemia. IJPSRR 2021 68 1 104 110
    [Google Scholar]
  46. Mishra PR Panda PK Apanna KC Panigrahi S 2011
  47. DiPiro J.T. Wells B.G. Schwinghammer T.L. DiPiro C.V. Pharmacotherapy handbook. Appleton & Lange 2000
    [Google Scholar]
  48. Chait A. Brunzell J.D. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol. Metab. Clin. North Am. 1990 19 2 259 278 10.1016/S0889‑8529(18)30324‑4 2192873
    [Google Scholar]
  49. Goodman L.S. Gilman A. The pharmacological basis of therapeutics. New York Macmillan 1970
    [Google Scholar]
  50. Hassan B. Overview on hyperlipidemia. J Chromat Separation Techniq 2013 4 2 1
    [Google Scholar]
  51. Vijayaraj P.S. Muthukumar K. Sabarirajan J. Naciappan V. IJBB 2011 48 54 58
    [Google Scholar]
  52. Kaliora A.C. Dedoussis G.V.Z. Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis 2006 187 1 1 17 10.1016/j.atherosclerosis.2005.11.001 16313912
    [Google Scholar]
  53. Dhuley J.N. Naik S.R. Rele S. Banerji A. Hypolipidaemic and antioxidant activity of diallyl disulphide in rats. Pharm. Pharmacol. Commun. 1999 5 12 689 696 10.1211/146080899128734406
    [Google Scholar]
  54. Shetgiri P.P. D’Mello P.M. Indian Drugs 2003 40 567 569
    [Google Scholar]
  55. Gopinathan N. Srinivasan K.K. Mathew J.E. Indian Drugs 2004 41 633 635
    [Google Scholar]
  56. Rajani G.P. Ashok P. In vitro antioxidant and antihyperlipidemic activities of Bauhinia variegata Linn. Indian J. Pharmacol. 2009 41 5 227 232 10.4103/0253‑7613.58513 20177495
    [Google Scholar]
  57. Singh R. Nain S. A mini review on hyperlipidemia: Common clinical problem. J. Interv. Cardiol. 2018 10 1 3
    [Google Scholar]
  58. Ranadive G.N. Lala A.K. Sterol-phospholipid interaction in model membranes: Role of C5-C6 double bond in cholesterol. Biochemistry 1987 26 9 2426 2431 10.1021/bi00383a005 3607024
    [Google Scholar]
  59. Haines T.H. Do sterols reduce proton and sodium leaks through lipid bilayers? Prog. Lipid Res. 2001 40 4 299 324 10.1016/S0163‑7827(01)00009‑1 11412894
    [Google Scholar]
  60. Esfahani M. Scerbo L. Devlin T.M. A requirement for cholesterol and its structural features for a human macrophage‐like cell line. J. Cell. Biochem. 1984 25 2 87 97 10.1002/jcb.240250204 6480716
    [Google Scholar]
  61. Vance D. Van den Bosch H. Cholesterol in the year 2000. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2000 1529 1-3 1 8 10.1016/S1388‑1981(00)00133‑5 11111073
    [Google Scholar]
  62. Yeagle P.L. Cholesterol and the cell membrane. Biochim. Biophys. Acta Rev. Biomembr. 1985 822 3-4 267 287 10.1016/0304‑4157(85)90011‑5 3904832
    [Google Scholar]
  63. Miao L. Nielsen M. Thewalt J. From lanosterol to cholesterol: Structural evolution and differential effects on lipid bilayers. Biophys. J. 2002 82 3 1429 1444 10.1016/S0006‑3495(02)75497‑0 11867458
    [Google Scholar]
  64. Awad A.B. Fink C.S. Phytosterols as anticancer dietary components: Evidence and mechanism of action. J. Nutr. 2000 130 9 2127 2130 10.1093/jn/130.9.2127 10958802
    [Google Scholar]
  65. Berge K.E. Tian H. Graf G.A. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000 290 5497 1771 1775 10.1126/science.290.5497.1771 11099417
    [Google Scholar]
  66. Simons K. Ehehalt R. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 2002 110 5 597 603 10.1172/JCI0216390 12208858
    [Google Scholar]
  67. Prior I.A. Hancock J.F. Compartmentalization of Ras proteins. J. Cell Sci. 2001 114 9 1603 1608 10.1242/jcs.114.9.1603 11309191
    [Google Scholar]
  68. Sundaram M. Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr. Metab. (Lond.) 2010 7 1 35 10.1186/1743‑7075‑7‑35 20423497
    [Google Scholar]
  69. Ridker P.M. Genest J. Boekholdt S.M. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial. Lancet 2010 376 9738 333 339 10.1016/S0140‑6736(10)60713‑1 20655105
    [Google Scholar]
  70. Mozaffarian D. Benjamin E.J. Go A.S. Heart disease and stroke statistics—2016 update: A report from the American Heart Association. Circulation 2016 133 4 e38 e360 10.1161/CIR.0000000000000350 26673558
    [Google Scholar]
  71. Centers for disease control and prevention (CDC). Vital signs: Prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. MMWR Morb. Mortal. Wkly. Rep. 2011 60 4 109 114 21293326
    [Google Scholar]
  72. Karr S. Epidemiology and management of hyperlipidemia. AJMC 2017 23 9 S139 S148 28978219
    [Google Scholar]
  73. Simons M. Keller P. Dichgans J. Schulz J.B. Cholesterol and Alzheimer’s disease. Neurology 2001 57 6 1089 1093 10.1212/WNL.57.6.1089 11571339
    [Google Scholar]
  74. Gupta R. Mohan I. Narula J. Trends in coronary heart disease epidemiology in India. Ann. Glob. Health 2016 82 2 307 315 10.1016/j.aogh.2016.04.002 27372534
    [Google Scholar]
  75. Keane W.F. St Peter J.V. Kasiske B.L. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Kidney Int. Suppl. 1992 38 S134 S141 1405364
    [Google Scholar]
  76. Nelson R.H. Hyperlipidemia as a risk factor for cardiovascular disease. Prim. Care 2013 40 1 195 211 10.1016/j.pop.2012.11.003 23402469
    [Google Scholar]
  77. Pettersson C. Studies on the atherogenicity of Apo B containing lipoproteins in type 2 diabetes Institute of Medicine. Department of Molecular and Clinical Medicine 2009
    [Google Scholar]
  78. Stone N.J. Robinson J.G. Lichtenstein A.H. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines. J. Am. Coll. Cardiol. 2014 63 25 2889 2934 10.1016/j.jacc.2013.11.002 24239923
    [Google Scholar]
  79. Ogden C.L. Carroll M.D. Kit B.K. Flegal K.M. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014 311 8 806 814 10.1001/jama.2014.732 24570244
    [Google Scholar]
  80. ACC/AHA 2016 www.cvriskcalculator.com
  81. Ito M.K. Watts G.F. Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia. Drugs 2015 75 15 1715 1724 10.1007/s40265‑015‑0466‑y 26370207
    [Google Scholar]
  82. Sjouke B. Kusters D.M. Kindt I. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: Prevalence, genotype–phenotype relationship, and clinical outcome. Eur. Heart J. 2015 36 9 560 565 10.1093/eurheartj/ehu058 24585268
    [Google Scholar]
  83. Nordestgaard B.G. Chapman M.J. Humphries S.E. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 2013 34 45 3478 3490 10.1093/eurheartj/eht273 23956253
    [Google Scholar]
  84. Khera A.V. Won H.H. Peloso G.M. Diagnostic yield and clinical utility of sequencing famil ial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 2016 67 22 2578 2589 10.1016/j.jacc.2016.03.520 27050191
    [Google Scholar]
  85. Naser I.H. Alkareem Z.A. Mosa A.U. Hyperlipidemia: Pathophysiology, causes, complications and treatment, A Review. J. Pharm. Pharm. Sci. 2021 ••• 118 132
    [Google Scholar]
  86. Hill M.F. Bordoni B. Hyperlipidemia. StatPearls. Treasure Island, FL StatPearls Publishing 2023
    [Google Scholar]
  87. Edeoga H.O. Okwu D.E. Mbaebie B.O. Phytochemical constituents of some Nigerian medicinal plants. AJB 2005 19 7 685 688
    [Google Scholar]
  88. Cunningham A.B. An investigation of the herbal medicine trade in Natal/KwaZulu. Institute of Natural Resources, University of Natal 1988
    [Google Scholar]
  89. Verma N. Introduction to hyperlipidemia and its treatment: A review. Int. J. Curr. Pharm. Res. 2016 9 1 6 14 10.22159/ijcpr.2017v9i1.16616
    [Google Scholar]
  90. Belay B. Belamarich P.F. Tom-Revzon C. The use of statins in pediatrics: Knowledge base, limitations, and future directions. Pediatrics 2007 119 2 370 380 10.1542/peds.2006‑0787 17272627
    [Google Scholar]
  91. Bersot T.P. Drug therapy for hypercholesterolemia and dyslipidemia Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. McGraw-Hill 2011 877 908
    [Google Scholar]
  92. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 2003 72 1 137 174 10.1146/annurev.biochem.72.121801.161712 12543708
    [Google Scholar]
  93. Safeer R.S. Lacivita C.L. Choosing drug therapy for patients with hyperlipidemia. Am. Fam. Physician 2000 61 11 3371 3382 10865931
    [Google Scholar]
  94. Harikumar K. Niveditha B. Reddy P.K. Int J Phytopharm 2012 3 3 256 262
    [Google Scholar]
  95. Ahmed S.M. Clasen M.D. Donnelly M.D. Managment of dyslipidemia in adults. Am. Fam. Physician 1998 57 1 16
    [Google Scholar]
  96. Diebold B.A. Bhagavan N.V. Guillory R.J. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. Biochim. Biophys. Acta, Gen. Subj. 1994 1200 2 100 108 10.1016/0304‑4165(94)90123‑6 8031828
    [Google Scholar]
  97. Nirosha K. Divya M. Vamsi S. Mohemmed S. A review on hyperlipidemia. Int. J. Novel Trends Pharm. Sci. 2014 4 5 81 92
    [Google Scholar]
  98. Onwe P.E. Folawiyo M.A. Anyigor-Ogah C.S. Umahi G. Okorocha A.E. Afoke A.O. J. Med. Dent. Sci. 2015 14 10 93 100
    [Google Scholar]
  99. Yuan G. Khalid Z. Hypertriglyceridemia: Its etiology, effects and treatment. Can Med Assoc 2007 176 8 1113 1120 10.1503/cmaj.060963
    [Google Scholar]
  100. Rubins H.B. Robins S.J. Collins D. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 2002 162 22 2597 2604 10.1001/archinte.162.22.2597 12456232
    [Google Scholar]
  101. Bhatt. Int. J. Physiol. Pathophysiol. Pharmacol. 2010 2 1 57 63 21383898
    [Google Scholar]
  102. Canner P.L. Berge K.G. Wenger N.K. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J. Am. Coll. Cardiol. 1986 8 6 1245 1255 10.1016/S0735‑1097(86)80293‑5 3782631
    [Google Scholar]
  103. Carlson L.A. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int. J. Clin. Pract. 2004 58 7 706 713 10.1111/j.1368‑5031.2004.00233.x 15311728
    [Google Scholar]
  104. Bélichard P. Pruneau D. Zhiri A. Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster. Biochim. Biophys. Acta Lipids Lipid Metab. 1993 1169 1 98 102 10.1016/0005‑2760(93)90087‑P 8334156
    [Google Scholar]
  105. McKenney J.M. Farnier M. Lo K.W. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 2006 47 8 1584 1587 10.1016/j.jacc.2005.11.072 16630994
    [Google Scholar]
  106. Goldberg I.J. Clinical review 124: Diabetic dyslipidemia: Causes and consequences. J. Clin. Endocrinol. Metab. 2001 86 3 965 971 10.1210/jcem.86.3.7304 11238470
    [Google Scholar]
  107. Ginsberg H.N. Diabetic dyslipidemia: Basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996 45 S27 S30 10.2337/diab.45.3.S27 8674885
    [Google Scholar]
  108. Krauss R.M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr. Opin. Lipidol. 1994 5 5 339 349 10.1097/00041433‑199410000‑00005 7858908
    [Google Scholar]
  109. Haffner S.M. Mykkänen L. Festa A. Burke J.P. Stern M.P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000 101 9 975 980 10.1161/01.CIR.101.9.975 10704163
    [Google Scholar]
  110. Dixon J.L. Furukawa S. Ginsberg H.N. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J. Biol. Chem. 1991 266 8 5080 5086 10.1016/S0021‑9258(19)67758‑6 1848237
    [Google Scholar]
  111. Taghibiglou C. Carpentier A. Van Iderstine S.C. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J. Biol. Chem. 2000 275 12 8416 8425 10.1074/jbc.275.12.8416 10722675
    [Google Scholar]
  112. De Man F.H.A.F. Castro Cabezas M. Van Barlingen H.H.J.J. Erkelens D.W. De Bruin T.W.A. Triglyceride‐rich lipoproteins in non‐insulin‐dependent diabetes mellitus: post‐prandial metabolism and relation to premature atherosclerosis. Eur. J. Clin. Invest. 1996 26 2 89 108 10.1046/j.1365‑2362.1996.114256.x 8904518
    [Google Scholar]
  113. Lewis G.F. O’Meara N.M. Soltys P.A. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J. Clin. Endocrinol. Metab. 1991 72 4 934 944 10.1210/jcem‑72‑4‑934 2005221
    [Google Scholar]
  114. Lewis G.F. O’Meara N.M. Cabana V.G. Postprandial triglyceride response in Type 1 (insulin-dependent) diabetes mellitus is not altered by short-term deterioration in glycaemic control or level of postprandial insulin replacement. Diabetologia 1991 34 4 253 259 10.1007/BF00405084 2065859
    [Google Scholar]
  115. Ebara T. Conde K. Kako Y. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J. Clin. Invest. 2000 105 12 1807 1818 10.1172/JCI8283 10862796
    [Google Scholar]
  116. Febbraio M. Abumrad N.A. Hajjar D.P. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 1999 274 27 19055 19062 10.1074/jbc.274.27.19055 10383407
    [Google Scholar]
  117. Ishida B.Y. Blanche P.J. Nichols A.V. Yashar M. Paigen B. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J. Lipid Res. 1991 32 4 559 568 10.1016/S0022‑2275(20)42043‑7 1856605
    [Google Scholar]
  118. Véniant M.M. Pierotti V. Newland D. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J. Clin. Invest. 1997 100 1 180 188 10.1172/JCI119511 9202070
    [Google Scholar]
  119. Goldberg I.J. Le N.A. Ginsberg H.N. Krauss R.M. Lindgren F.T. Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey. J. Clin. Invest. 1988 81 2 561 568 10.1172/JCI113354 3276735
    [Google Scholar]
/content/journals/cdr/10.2174/0115733998289406240214093815
Loading
Effects of Diabetes and Hyperlipidemia in Physiological Conditions - A Review
Bentham Science Publishers ; https://doi.org/10.2174/0115733998289406240214093815
/content/journals/cdr/10.2174/0115733998289406240214093815
/content/journals/cdr/10.2174/0115733998289406240214093815
Loading

Data & Media loading...

  • Article Type: Review Article
Keywords: hyperglycemia ; autoimmune ; Diabetes ; hyperlipidemia ; ketoacidosis ; insulin secretion

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test